Skip to main content
Hanmi Pharm. Co., Ltd. logo

Hanmi Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 128940 ISIN · KR7128940004 LEI · 988400PP10VZVUOFE672 KO Manufacturing
Open in API
Filings indexed 509 across all filing types
Latest filing 2026-03-25 Major Shareholding Noti…
Country KR South Korea
Listing KO 128940

About Hanmi Pharm. Co., Ltd.

https://www.hanmipharm.com/

Hanmi Pharm. Co., Ltd. is a research-oriented biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products. Its portfolio includes prescription drugs, over-the-counter (OTC) medicines, and raw materials. The company dedicates a significant portion of its revenue to in-house research and development, creating a robust pipeline of innovative therapies. A key unique selling point is its proprietary LAPSCOVERY platform technology, which is used to develop long-acting biologics. Hanmi's R&D efforts are concentrated on key therapeutic areas, including metabolic diseases, oncology, and rare diseases. The company actively collaborates with global partners to advance its clinical programs and bring novel treatments to the market.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 90% confidence The document is a detailed ‘주식등의 대량보유상황보고서(약식)’ (Report on large holdings of shares etc.) filed by the National Pension Service disclosing changes in its shareholding percentage in Hanmi Pharm pursuant to Korea’s Capital Markets Act. It is not an announcement of a report publication but the full regulatory filing of a major shareholding notification crossing threshold levels. This matches the Major Shareholding Notification category.
2026-03-25 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 98% confidence The document is a formal 'Audit Report' (감사보고서) for Hanmi Pharmaceutical Co., Ltd. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and accompanying notes. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typically found in a full 10-K, focusing specifically on the audit and financial data. Therefore, it is classified as an Audit Report. FY 2025
2026-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding Hanmi Pharmaceutical. This type of filing is specifically used to report changes in significant share ownership (crossing thresholds) by major shareholders, which aligns with the 'Major Shareholding Notification' category.
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, equity, profit/loss) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure form used in Korea to announce the receipt and filing of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding their holdings in Hanmi Pharmaceutical. This type of filing is a standard regulatory disclosure for major shareholders (those holding 10% or more) to report changes in their share ownership, which falls under the 'Major Shareholding Notification' category.
2026-03-17 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Hanmi Pharmaceutical. It contains the agenda for the 16th Annual General Meeting, including items such as the approval of financial statements, election of directors, and remuneration limits. It also includes detailed management information, board activity reports, and financial statements (balance sheet and income statement) as part of the meeting materials provided to shareholders. This document is a comprehensive information package for an upcoming AGM, fitting the 'AGM Information' category.
2026-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.